Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 269

1.

Regulatory action on rosiglitazone by the U.S. Food and Drug Administration.

Woodcock J, Sharfstein JM, Hamburg M.

N Engl J Med. 2010 Oct 14;363(16):1489-91. doi: 10.1056/NEJMp1010788. Epub 2010 Sep 23. No abstract available.

PMID:
20942663
[PubMed - indexed for MEDLINE]
Free Article
2.

Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes.

Hu YY, Ye SD, Zhao LL, Zheng M, Wu FZ, Chen Y.

Clin Endocrinol (Oxf). 2010 Dec;73(6):739-43. doi: 10.1111/j.1365-2265.2010.03878.x.

PMID:
20874769
[PubMed - indexed for MEDLINE]
3.

Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes [Internet].

Qayyum R, Wilson LM, Bolen S, Maruthur N, Marinopoulos SS, Feldman L, Ranasinghe P, Amer M, Bass EB.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Sep.

PMID:
20704037
[PubMed]
Books & Documents
4.

Revisiting the rosiglitazone story--lessons learned.

Rosen CJ.

N Engl J Med. 2010 Aug 26;363(9):803-6. doi: 10.1056/NEJMp1008233. Epub 2010 Jul 21. No abstract available.

PMID:
20660395
[PubMed - indexed for MEDLINE]
Free Article
5.

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

Nissen SE, Wolski K.

Arch Intern Med. 2010 Jul 26;170(14):1191-1201. doi: 10.1001/archinternmed.2010.207. Review.

PMID:
20656674
[PubMed - indexed for MEDLINE]
6.

Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study.

Sillars B, Davis WA, Hirsch IB, Davis TM.

Diabetes Obes Metab. 2010 Sep;12(9):757-65. doi: 10.1111/j.1463-1326.2010.01230.x.

PMID:
20649627
[PubMed - indexed for MEDLINE]
7.

Outcomes of genetic testing in adults with a history of venous thromboembolism.

Segal JB, Brotman DJ, Emadi A, Necochea AJ, Samal L, Wilson LM, Crim MT, Bass EB.

Evid Rep Technol Assess (Full Rep). 2009 Jun;(180):1-162. Review.

PMID:
20629476
[PubMed - indexed for MEDLINE]
Free Article
8.

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA.

JAMA. 2010 Jul 28;304(4):411-8. doi: 10.1001/jama.2010.920. Epub 2010 Jun 28.

PMID:
20584880
[PubMed - indexed for MEDLINE]
9.

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials.

Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G; ADOPT Study Group; RECORD Steering Committee.

Diabetologia. 2010 Sep;53(9):1838-45. doi: 10.1007/s00125-010-1804-y. Epub 2010 Jun 8.

PMID:
20532476
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.

Loebstein R, Dushinat M, Vesterman-Landes J, Silverman B, Friedman N, Katzir I, Kurnik D, Lomnicky Y, Kokia E, Halkin H.

J Clin Pharmacol. 2011 Feb;51(2):173-80. doi: 10.1177/0091270010368281. Epub 2010 May 19.

PMID:
20484611
[PubMed - indexed for MEDLINE]
11.

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.

Seck T, Nauck M, Sheng D, Sunga S, Davies MJ, Stein PP, Kaufman KD, Amatruda JM; Sitagliptin Study 024 Group.

Int J Clin Pract. 2010 Apr;64(5):562-76. doi: 10.1111/j.1742-1241.2010.02353.x.

PMID:
20456211
[PubMed - indexed for MEDLINE]
12.

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.

Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davies M; 1860-LIRA-DPP-4 Study Group.

Lancet. 2010 Apr 24;375(9724):1447-56. doi: 10.1016/S0140-6736(10)60307-8. Erratum in: Lancet. 2010 Jul 24;376(9737):234.

PMID:
20417856
[PubMed - indexed for MEDLINE]
13.

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.

Williams-Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ, Amatruda JM.

Diabetes Obes Metab. 2010 May;12(5):442-51. doi: 10.1111/j.1463-1326.2010.01204.x.

PMID:
20415693
[PubMed - indexed for MEDLINE]
14.

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.

Phung OJ, Scholle JM, Talwar M, Coleman CI.

JAMA. 2010 Apr 14;303(14):1410-8. doi: 10.1001/jama.2010.405.

PMID:
20388897
[PubMed - indexed for MEDLINE]
15.

Long-term metformin use is associated with decreased risk of breast cancer.

Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR.

Diabetes Care. 2010 Jun;33(6):1304-8. doi: 10.2337/dc09-1791. Epub 2010 Mar 18.

PMID:
20299480
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.

Seino Y, Rasmussen MF, Nishida T, Kaku K.

Curr Med Res Opin. 2010 May;26(5):1013-22. doi: 10.1185/03007991003672551.

PMID:
20199137
[PubMed - indexed for MEDLINE]
17.

Exenatide versus glibenclamide in patients with diabetes.

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.

Diabetes Technol Ther. 2010 Mar;12(3):233-40. doi: 10.1089/dia.2009.0141.

PMID:
20151774
[PubMed - indexed for MEDLINE]
18.

The evolving place of incretin-based therapies in type 2 diabetes.

Gallwitz B.

Pediatr Nephrol. 2010 Jul;25(7):1207-17. doi: 10.1007/s00467-009-1435-z. Epub 2010 Feb 4. Review.

PMID:
20130920
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.

Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP, Home PD.

Eur Heart J. 2010 Apr;31(7):824-31. doi: 10.1093/eurheartj/ehp604. Epub 2010 Jan 29.

PMID:
20118174
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes.

Blevins T.

Postgrad Med. 2010 Jan;122(1):172-83. doi: 10.3810/pgm.2010.01.2111. Review.

PMID:
20107301
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk